


Study design LUMEN-1 (EORTC 2334)



Stratification:

- Country
- WHO grade 1 vs 2/3
- Age (\leq , > 60)
- Performance status (0, >0)
- Size (\leq , >43 mm)
- Primary endpoint: Progression-free survival (RANO meningioma criteria)
- Secondary endpoints: Response rate, OS, safety, HRQoL, neurological function
- Exploratory analyses: validation of tissue-based factors (methylation, genetic profiling), prognostic and predictive value of SSTR-PET, validation of PET-based response criteria, correlation of dosimetry with outcome, investigation of 3D volumetry